Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 201

1.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv192-iv237. doi: 10.1093/annonc/mdy275. No abstract available.

PMID:
30285222
2.

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer.

Loong HH, Kwan SS, Mok TS, Lau YM.

Curr Treat Options Oncol. 2018 Sep 29;19(11):58. doi: 10.1007/s11864-018-0570-9. Review.

PMID:
30267319
3.

Novel method for rapid identification of micropapillary or solid components in early-stage lung adenocarcinoma.

Zhao ZR, Lau RWH, Long H, Mok TSK, Chen GG, Underwood MJ, Ng CSH.

J Thorac Cardiovasc Surg. 2018 Dec;156(6):2310-2318.e2. doi: 10.1016/j.jtcvs.2018.07.054. Epub 2018 Aug 2.

PMID:
30180981
4.

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, Bai H, Tian Y, Wan R, Han M, Cao Y, Xiong L, Liu L, Wang S, Cai S, Mok TSK, Wang J.

Cancer Res. 2018 Nov 15;78(22):6486-6496. doi: 10.1158/0008-5472.CAN-18-1814. Epub 2018 Aug 31.

PMID:
30171052
5.

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Wu YL, Ahn MJ, Garassino MC, Han JY, Katakami N, Kim HR, Hodge R, Kaur P, Brown AP, Ghiorghiu D, Papadimitrakopoulou VA, Mok TSK.

J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.

PMID:
30059262
6.

Is the LENT Score Already Outdated?

Rozman A, Mok TSK.

Respiration. 2018;96(4):303-304. doi: 10.1159/000491678. Epub 2018 Jul 26. No abstract available.

PMID:
30048988
7.

Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

Soria JC, Ho SN, Varella-Garcia M, Iafrate AJ, Solomon BJ, Shaw AT, Blackhall F, Mok TS, Wu YL, Pestova K, Wilner KD, Polli A, Paolini J, Lanzalone S, Green S, Camidge DR.

Ann Oncol. 2018 Sep 1;29(9):1964-1971. doi: 10.1093/annonc/mdy242.

PMID:
30010763
8.

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.

Wu YL, Lu S, Lu Y, Zhou J, Shi YK, Sriuranpong V, Ho JCM, Ong CK, Tsai CM, Chung CH, Wilner KD, Tang Y, Masters ET, Selaru P, Mok TS.

J Thorac Oncol. 2018 Oct;13(10):1539-1548. doi: 10.1016/j.jtho.2018.06.012. Epub 2018 Aug 14.

PMID:
29966800
9.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

10.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
11.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL.

J Clin Oncol. 2018 Aug 1;36(22):2244-2250. doi: 10.1200/JCO.2018.78.7994. Epub 2018 Jun 4.

PMID:
29864379
12.

Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.

Loong HH, Raymond VM, Shiotsu Y, Chua DTT, Teo PML, Yung T, Skrzypczak S, Lanman RB, Mok TSK.

Clin Lung Cancer. 2018 Sep;19(5):e601-e608. doi: 10.1016/j.cllc.2018.04.022. Epub 2018 May 7.

PMID:
29807856
13.

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS.

J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.

PMID:
29768118
14.

Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.

Chan AWH, Tong JHM, Kwan JSH, Chow C, Chung LY, Chau SL, Lung RWM, Ng CSH, Wan IYP, Mok TSK, To KF.

Mod Pathol. 2018 Sep;31(9):1381-1390. doi: 10.1038/s41379-018-0053-3. Epub 2018 Apr 30.

PMID:
29713040
15.

Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy.

Shukla ND, Salahudeen AA, Taylor GA, Ramalingam SS, Vokes EE, Goss GD, Decker RH, Kelly K, Scagliotti GV, Mok TS, Wakelee HA.

Clin Lung Cancer. 2018 Sep;19(5):377-386. doi: 10.1016/j.cllc.2018.03.004. Epub 2018 Mar 17. Review.

16.

Overview of current systemic management of EGFR-mutant NSCLC.

Hsu WH, Yang JC, Mok TS, Loong HH.

Ann Oncol. 2018 Jan 1;29(suppl_1):i3-i9. doi: 10.1093/annonc/mdx702.

PMID:
29462253
17.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Cajal SRY, Frias A, Cao P, Rosell R.

EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.

18.

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI.

Cheong HT, Xu F, Choy CT, Hui CWC, Mok TSK, Wong CH.

Oncol Lett. 2018 Jan;15(1):901-907. doi: 10.3892/ol.2017.7377. Epub 2017 Nov 9.

19.

Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.

Wu YL, Mok TS.

Lancet Oncol. 2018 Jan;19(1):e5. doi: 10.1016/S1470-2045(17)30924-5. No abstract available.

PMID:
29304363
20.

Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.

Li L, Xu J, Qiu G, Ying J, Du Z, Xiang T, Wong KY, Srivastava G, Zhu XF, Mok TS, Chan AT, Chan FK, Ambinder RF, Tao Q.

Theranostics. 2018 Jan 1;8(1):61-77. doi: 10.7150/thno.20893. eCollection 2018.

21.

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC.

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.

PMID:
29290252
22.

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI.

Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C.

Clin Drug Investig. 2018 Apr;38(4):319-331. doi: 10.1007/s40261-017-0611-3.

23.

De-novo and acquired resistance to immune checkpoint targeting.

Syn NL, Teng MWL, Mok TSK, Soo RA.

Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. Review.

PMID:
29208439
24.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T.

Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419.

25.

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC.

J Clin Oncol. 2017 Dec 20;35(36):4027-4034. doi: 10.1200/JCO.2017.73.9250. Epub 2017 Oct 2.

PMID:
28968167
26.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.

Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

PMID:
28958502
27.

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.

Li C, Huang C, Mok TS, Zhuang W, Xu H, Miao Q, Fan X, Zhu W, Huang Y, Lin X, Jiang K, Hu D, Chen X, Huang P, Lin G.

J Thorac Oncol. 2017 Oct;12(10):1536-1543. doi: 10.1016/j.jtho.2017.07.015. Epub 2017 Jul 24.

28.

A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Chan SL, Yeo W, Mo F, Chan AWH, Koh J, Li L, Hui EP, Chong CCN, Lai PBS, Mok TSK, Yu SCH.

Cancer. 2017 Oct 15;123(20):3977-3985. doi: 10.1002/cncr.30825. Epub 2017 Jun 22.

29.

Osimertinib in EGFR T790M-Positive Lung Cancer.

Mok TS, Wu YL, Papadimitrakopoulou VA.

N Engl J Med. 2017 May 18;376(20):1993-4. doi: 10.1056/NEJMc1703339. No abstract available.

30.

The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.

Chan OSH, Lee VHF, Mok TSK, Mo F, Chang ATY, Yeung RMW.

Clin Oncol (R Coll Radiol). 2017 Sep;29(9):568-575. doi: 10.1016/j.clon.2017.04.035. Epub 2017 May 9.

PMID:
28499791
31.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

32.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.

Cancer Treat Rev. 2017 Apr;55:181-189. doi: 10.1016/j.ctrv.2017.03.006. Epub 2017 Mar 30. Review.

33.

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, Chewaskulyong B, Sunpaweravong P, Ohe Y, Ichinose Y, Yang JJ, Mok TS, Young H, Haddad V, Rukazenkov Y, Fukuoka M.

Lung Cancer. 2017 Feb;104:119-125. doi: 10.1016/j.lungcan.2016.11.022. Epub 2016 Nov 30.

34.

SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma.

Luo Y, Mok TS, Lin X, Zhang W, Cui Y, Guo J, Chen X, Zhang T, Wang T.

Sci Rep. 2017 Jan 24;7:41191. doi: 10.1038/srep41191.

35.

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.

Zhao ZR, Situ DR, Lau RWH, Mok TSK, Chen GG, Underwood MJ, Ng CSH.

J Thorac Oncol. 2017 May;12(5):890-896. doi: 10.1016/j.jtho.2017.01.012. Epub 2017 Jan 20.

36.

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators.

N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.

37.

Corrigendum: Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q.

Sci Rep. 2016 Oct 6;6:34435. doi: 10.1038/srep34435. No abstract available.

38.

Is there significance in identification of non-predominant micropapillary or solid components in early-stage lung adenocarcinoma?

Zhao ZR, To KF, Mok TS, Ng CS.

Interact Cardiovasc Thorac Surg. 2017 Jan;24(1):121-125. doi: 10.1093/icvts/ivw283. Epub 2016 Sep 5. Review.

PMID:
27600912
39.

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Salahudeen AA, Patel MI, Baas P, Curran WJ, Bradley JD, Gandara DR, Goss GD, Mok TS, Ramalingam SS, Vokes EE, Malik SM, Wakelee HA.

Clin Lung Cancer. 2017 Jan;18(1):5-12. doi: 10.1016/j.cllc.2016.06.007. Epub 2016 Jun 27. Review.

40.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.

Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K.

J Thorac Oncol. 2016 Oct;11(10):1736-44. doi: 10.1016/j.jtho.2016.05.038. Epub 2016 Jul 21.

41.

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM.

J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009. Epub 2016 Jul 9. Review.

42.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

43.

Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers.

Li L, Li C, Mao H, Du Z, Chan WY, Murray P, Luo B, Chan AT, Mok TS, Chan FK, Ambinder RF, Tao Q.

Sci Rep. 2016 May 26;6:26591. doi: 10.1038/srep26591. Erratum in: Sci Rep. 2016 Oct 06;6:34435.

44.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.

J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28.

PMID:
27022118
45.

Scientific Advances in Lung Cancer 2015.

Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI.

J Thorac Oncol. 2016 May;11(5):613-638. doi: 10.1016/j.jtho.2016.03.012. Epub 2016 Mar 22. Review.

46.

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.

Tong JH, Yeung SF, Chan AW, Chung LY, Chau SL, Lung RW, Tong CY, Chow C, Tin EK, Yu YH, Li H, Pan Y, Chak WP, Ng CS, Mok TS, To KF.

Clin Cancer Res. 2016 Jun 15;22(12):3048-56. doi: 10.1158/1078-0432.CCR-15-2061. Epub 2016 Feb 4.

47.

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.

Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS.

J Thorac Oncol. 2015 Dec;10(12):1745-53. doi: 10.1097/JTO.0000000000000693.

48.

Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

Mok TS, Loong HH.

Lancet. 2016 Apr 9;387(10027):1488-90. doi: 10.1016/S0140-6736(15)01308-2. Epub 2015 Dec 19. No abstract available.

PMID:
26712085
49.

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography.

Tan DS, Mok TS, Rebbeck TR.

J Clin Oncol. 2016 Jan 1;34(1):91-101. doi: 10.1200/JCO.2015.62.0096. Epub 2015 Nov 17. Review.

PMID:
26578615
50.

Special Issue on Global Cancer Medicine.

Shulman LN, Mok TS.

J Clin Oncol. 2016 Jan 1;34(1):1-2. doi: 10.1200/JCO.2015.64.6067. Epub 2015 Nov 17. No abstract available.

PMID:
26578609

Supplemental Content

Support Center